Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OpGen Inc OPGN

Healthcare Biotechnology
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's... see more

Recent & Breaking News (OTCPK:OPGN)

OpGen Provides Further Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

GlobeNewswire March 24, 2020

OpGen Data Predicting Phenotypic Antimicrobial Susceptibility Published in Diagnostic Microbiology & Infectious Disease Journal

GlobeNewswire March 23, 2020

OpGen Provides Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

GlobeNewswire March 19, 2020

OpGen Provides Update on Curetis Now Offering BGI's CE-IVD Rapid Test Kit for Coronavirus in Europe

GlobeNewswire March 16, 2020

Global Markets Are In Turmoil Sending Investors Scrambling For A Safe Haven

Livemoney March 13, 2020

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2019

GlobeNewswire March 12, 2020

Curetis N.V. Shareholders Approve Planned Business Combination with OpGen

GlobeNewswire March 10, 2020

OpGen Provides Update on Curetis Preliminary, Unaudited 2019 Condensed Combined Key Financials and Business Update

GlobeNewswire February 20, 2020

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2019 and Provides Business Update

GlobeNewswire February 12, 2020

OpGen Provides Update on Curetis Group Company Ares Genetics' Collaboration with BGI Group to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe

GlobeNewswire January 30, 2020

OpGen Achieves Key Milestone in Planned Business Combination with Curetis

GlobeNewswire January 28, 2020

OpGen Provides Update on Curetis Group Business Receiving U.S. FDA 510(k) Clearance of its Unyvero LRT for BAL Specimens

GlobeNewswire December 23, 2019

OpGen Provides Curetis Group Business Update and Announces Completion of Key Milestones in Planned Business Combination

GlobeNewswire December 2, 2019

OpGen Products in Development to Address "Urgent Threat" Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats

GlobeNewswire November 19, 2019

OpGen Reports Third Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire November 6, 2019

OpGen Provides Update on Curetis Group Company Ares Genetics Business

GlobeNewswire November 4, 2019

OpGen Announces Date of Third Quarter 2019 Financial Results Conference Call

GlobeNewswire October 29, 2019

OpGen Announces Closing of $9.4 Million Underwritten Public Offering

GlobeNewswire October 28, 2019

OpGen Announces Pricing of $9.4 Million Underwritten Offering

GlobeNewswire October 23, 2019

U.S. Patent Allowed Covering Acuitas Lighthouse® Software

GlobeNewswire October 23, 2019